This study provides preliminary clinical evidence that standardized Orthosiphon stamineus extract may meaningfully reduce serum uric acid in hyperuricemic adults.

Integrating predictive analytics, reinforcement learning, and causal inference improves maternal outcomes by aligning risk prediction with real-time, equity-aware resource allocation decisions.

Multimodal, precision-guided angiogenic therapies—gene, cell, extracellular vesicle, and biomaterial-based—offer transformative potential for treating ischemic diseases where revascularization remains unfeasible.

This study demonstrates interpretable, robust modeling for Parkinson’s telemonitoring, guiding reliable disease progression prediction under small-sample longitudinal data constraints.

Spatial transcriptomics reveals disease architecture at cellular resolution, but cost, FFPE limits, and complexity keep it from routine clinical diagnostics.

This review reframes chronic neurodegenerative and autoimmune disease through a reproducible, microbiome-centered mechanistic and therapeutic lens.

Spatial multi-omics repositions tissue context as a first-class clinical variable, but equitable, standardized translation remains unfinished business.

Intercellular mitochondrial transfer sustains tissue bioenergetics and immunity, offering a transformative, biologically grounded therapeutic strategy for degenerative and ischemic disease.

Protein language models can resolve uncertain BRCA variants rapidly, potentially widening equitable access to PARP-inhibitor therapy worldwide.

Closing AI's reproducibility and fairness gaps is a precondition, not an afterthought, for trusting deep-learning imaging tools at the bedside.

Explains why highly accurate AI resistance models fail clinically, and outlines concrete validation, equity, and deployment fixes.

Artificial-intelligence risk models and digital twins could shift cardiology from reactive treatment toward proactive, individualized prevention — if bias, validation, and trust gaps are honestly addressed.

Organoid-on-chip systems merge biological fidelity with engineering precision, offering AI-augmented, human-relevant platforms positioned to reshape preclinical drug development.

Novel antimicrobials show promise against multidrug-resistant infections in immunocompromised patients, yet gaps in stewardship, resistance, and equity persist.

AMR is outpacing critical-care antibiotics; precision genomic, antibody, peptide, and nanozyme strategies may restore therapeutic options.

Frailty-based, mechanism-anchored prescribing frameworks could replace single-disease guidelines that quietly harm complex older patients.

Restoring mitochondrial-nuclear communication through PINK1/Parkin, Nrf2, and mitophagy pathways offers a unifying, druggable strategy for Parkinson's disease modification.

Ignoring sex and gender in drug research skews dosing, safety data, and treatment efficacy — precision medicine cannot ignore this variable.

Cellular senescence organizes IPF pathogenesis across cell types, positioning senotherapeutics and regenerative cell therapy as biologically grounded strategies for reversing, not merely slowing, fibrosis.

RNA modifications reprogram liver-cancer transcripts to drive growth, immune escape, and drug resistance—offering new biomarkers and druggable targets.

Tissue-resident memory T cells permanently guard peripheral organs, but their dysregulation drives chronic autoimmune disease, making them a precise emerging therapeutic target.

Bariatric-level pharmacotherapy now exists, yet muscle loss, rebound, cost, and pediatric uncertainty still limit its real-world promise.

Environmental exposures converge with genetic risk to trigger autoimmune flares, guiding precision prevention beyond genetics alone.

STAG2/cohesin loss and oncofusion proteins collapse 3D chromatin loops in AML, silencing differentiation genes while revealing druggable, reversible epigenetic vulnerabilities.

Wearable digital biomarkers show strong clinical validity but require standardized validation, interoperable data systems, and equitable design before routine adoption.

Extracellular vesicles promise cell-free precision diagnostics and therapeutics, but standardization, scalability, and regulatory gaps still block routine clinical adoption.

Bridges experimental and computational toxicology to enable predictive, human-relevant risk assessment frameworks for safer and faster chemical evaluation

Epigenetic clocks convert DNA methylation into a modifiable biomarker, repositioning ageing as a treatable clinical target.

Non-coding RNA networks orchestrate pancreatic cancer progression, immune evasion, and chemoresistance, revealing druggable nodes for precision therapy.

This study integrates biomedical and ecological research, revealing shared biological mechanisms that inform therapeutic innovation, sustainable agriculture, and systems-level understanding of complex biological interactions.

Epigenome editing may silence sickle-globin defects without DNA cleavage, offering a safer, durable alternative to nuclease-based gene therapy.

Mapping how ALS/FTD proteins phase-separate and solidify reveals shared biophysical vulnerabilities that could be therapeutically exploited across the disease spectrum.

Reframing Long COVID as a biologically stratifiable network disorder could finally make targeted, effective treatment trials possible.

Mapping senescent-cell heterogeneity to precision senotherapies could transform multimorbid, age-related disease treatment safely

This study demonstrates that dietary bioactive compounds play a significant role in reducing the risk of chronic diseases, improving cardiovascular health, and offering protective effects against certain types of cancer.

AI compresses AMR diagnosis and discovery timelines dramatically, yet no tool has reached regulatory clearance — validation and trust, not algorithms, remain the bottleneck.

Integrating transcriptomic, epigenetic, and functional organoid data with genomics may finally close oncology’s persistent gap between diagnosis and matched treatment.